Coya Therapeutics, Inc. (COYA)

Over the past six months, Coya Therapeutics' stock has been impacted by several events. In January 2026, the company announced an $11.1 million private placement, the CEO issued a letter to stockholders, results were reported from an investigator-initiated study, and the FDA accepted an IND application for COYA 302 for FTD. In December 2025, Health Canada accepted a CTA to proceed with the COYA 302 ALSTARS Trial for ALS, and patients were dosed in the trial. In November 2025, Q3 2025 earnings were reported with an EPS of -$0.10 and quarterly revenue of $3.56 million, and a corporate update was provided. In September 2025, patient enrollment was completed for an investigator-initiated study in FTD patients, and the company participated in investor conferences. In August 2025, the FDA accepted an IND application for COYA 302 for ALS, and the partnership with Dr. Reddy's Laboratories was discussed. In July 2025, the pipeline and intellectual property portfolio were expanded with new US patent filings for COYA 301 in combination with GLP-1 RAs. The stock's 52-week range has been between $3.94 and $8.29, and as of February 6, 2026, the closing price was $4.41.

As a clinical-stage biotechnology company, the demand for Coya Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the prevalence and progression of the diseases it aims to treat, as well as the efficacy and regulatory approval of its therapeutic candidates. Therefore, there is no discernible demand seasonality for Coya Therapeutics' offerings.

Coya Therapeutics, Inc., established in 2020, is a clinical-stage biotechnology company focused on developing pharmaceutical solutions that modulate regulatory T cells (Tregs) to address severe neurodegenerative, autoimmune, and metabolic disorders. The company's core approach centers on the idea that dysfunctional Tregs contribute to chronic systemic and neuro-inflammation, which plays a central role in these diseases. Coya Therapeutics operates within the biotechnology sector, specifically the pharmaceutical industry. The company's product candidate pipeline leverages multiple therapeutic modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Key product candidates include COYA 101, COYA 301, COYA 302, COYA 303, COYA 201, and COYA 206.

Coya Therapeutics, Inc. is headquartered in Houston, Texas. The company has a licensing agreement with Dr. Reddy's Laboratories for COYA 302 in ALS patients across the U.S., Canada, EU, and U.K., indicating an international market reach for this specific product candidate.

In the past year, Coya Therapeutics has generally maintained a positive brand reputation, primarily driven by advancements in its clinical pipeline and regulatory successes. Key events contributing to its reputation include successful meetings with the FDA, expansion of the COYA 302 pipeline, expansion of its patent estate, presentation of data at the AD/PD 2024 Conference, FDA acceptance of the IND application for COYA 302 for ALS, completion of patient enrollment in an investigator-initiated study for FTD, Health Canada's acceptance of the COYA 302 clinical trial application for ALS, positive results from an investigator-initiated study of COYA 302 in FTD patients, and FDA acceptance of the IND application for COYA 302 for FTD. These developments highlight the company's progress in addressing significant unmet medical needs in neurodegenerative and autoimmune diseases.

Coya Therapeutics, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Approximately 22.73% to 24.03% of the company's stock is owned by institutional investors. Individual insider ownership accounts for about 0.26% to 10.32% of the stock. Retail investors hold a substantial portion, ranging from 66.95% to 75.71%.